The estimated Net Worth of Matthew R. Kwietniak is at least $261 Tisíc dollars as of 12 July 2024. Mr Kwietniak owns over 881 units of Avid Bioservices Inc stock worth over $251,400 and over the last few years he sold CDMO stock worth over $9,124.
Sign up
Mr Kwietniak CDMO stock SEC Form 4 insiders trading
Mr has made over 13 trades of the Avid Bioservices Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 881 units of CDMO stock worth $9,339 on 12 July 2024.
The largest trade he's ever made was exercising 10,365 units of Avid Bioservices Inc stock on 28 June 2023 worth over $109,869. On average, Mr trades about 1,830 units every 27 days since 2023. As of 12 July 2024 he still owns at least 23,717 units of Avid Bioservices Inc stock.
You can see the complete history of Mr Kwietniak stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Matthew Kwietniak biography
Matthew Kwietniak is the Chief Commercial Officer at Avid Bioservices Inc.
What's Mr Kwietniak's mailing address?
Matthew's mailing address filed with the SEC is 14191, Myford Road, Walnut, Tustin, Orange County, California, 92780, United States.
Insiders trading at Avid Bioservices Inc
Over the last 7 years, insiders at Avid Bioservices Inc have traded over $1,839,814 worth of Avid Bioservices Inc stock and bought 460,748 units worth $3,573,760 . The most active insiders traders include Gregory Sargen, Nicholas Stewart Green a Mark R Bamforth. On average, Avid Bioservices Inc executives and independent directors trade stock every 16 days with the average trade being worth of $107,028. The most recent stock trade was executed by Richard A. Richieri on 12 July 2024, trading 1,469 units of CDMO stock currently worth $15,571.
What does Avid Bioservices Inc do?
avid bioservices, a subsidiary of peregrine pharmaceuticals, inc. (nasdaq: pphm), is a unique contract manufacturing organization ("cmo") partner dedicated to the development and production of monoclonal antibodies, recombinant proteins and enzymes produced in mammalian cell culture. our extensive experience at all stages of development enables us to provide comprehensive development, manufacturing and support services to navigate a biologic from concept to commercialization.
What does Avid Bioservices Inc's logo look like?
Complete history of Mr Kwietniak stock trades at Avid Bioservices Inc
Avid Bioservices Inc executives and stock owners
Avid Bioservices Inc executives and other stock owners filed with the SEC include:
-
Nicholas Stewart Green B.Sc., MBA,
Pres, CEO & Director -
Mark Ziebell,
Vice President, General Counsel, Corporate Secretary -
Daniel R. Hart,
Chief Financial Officer -
Daniel Hart,
Chief Financial Officer -
Richard Hancock,
Director -
Mark R. Ziebell J.D.,
VP, Gen. Counsel & Corp. Sec. -
Catherine Mackey,
Independent Director -
Richard Richieri,
Chief Operations Officer -
Joseph Carleone,
Independent Non-Executive Chairman of the Board -
Gregory Sargen,
Independent Director -
Patrick Walsh,
Independent Director -
Mark Bamforth,
Independent Director -
Stephanie Diaz,
Investor Relations / Corporate Communications -
Timothy Compton,
Chief Commercial Officer -
Nicholas Green,
President, Chief Executive Officer, Director -
Prof. Alan J. Schroit,
Medical & Scientific Advisor -
Dr. Harold F. Dvorak,
Medical & Scientific Advisor -
Tracy L. Kinjerski,
VP of Bus. Operations -
Dr. Shelley P. M. Fussey,
VP of Intellectual Property -
Matthew Kwietniak,
Chief Commercial Officer -
Lorna Larson,
Sr. Director of HR -
Richard Richieri,
Chief Operations Officer -
Joel Mc Comb,
Director -
Roger J. Lias,
President & CEO -
Esther M. Alegria,
Director -
Jeanne Thoma,
Director -
Matthew R. Kwietniak,
Chief Commercial Officer